Drug
Everolimus clinical trials
Also written RAD001, Afinitor and Certican.
- studies test it
- 667
- open now
- 47
- in phase 3
- 83
- first study started
- 2000
Keep track of what changes. Save the Everolimus studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
665 studies that test it; most in 2010 (77)
| Year | Studies |
|---|---|
| 2000 | 1 |
| 2001 | 2 |
| 2003 | 3 |
| 2004 | 14 |
| 2005 | 26 |
| 2006 | 33 |
| 2007 | 31 |
| 2008 | 57 |
| 2009 | 74 |
| 2010 | 77 |
| 2011 | 54 |
| 2012 | 55 |
| 2013 | 40 |
| 2014 | 41 |
| 2015 | 26 |
| 2016 | 23 |
| 2017 | 22 |
| 2018 | 8 |
| 2019 | 11 |
| 2020 | 8 |
| 2021 | 10 |
| 2022 | 7 |
| 2023 | 11 |
| 2024 | 12 |
| 2025 | 7 |
| 2026 | 12 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 9
- Phase 1
- 215
- Phase 2
- 352
- Phase 3
- 83
- Phase 4
- 80
- No phase
- 21
What it is tested for
Each study’s main condition, where its own words name it.
- Lymphoma
- 10
Who runs them
Industry 148 · Other 519
Novartis Pharmaceuticals (117) · M.D. Anderson Cancer Center (33) · Dana-Farber Cancer Institute (16) · Memorial Sloan Kettering Cancer Center (16) · Emory University (13) · Fudan University (11) · SCRI Development Innovations, LLC (10) · Mayo Clinic (9)
Often tested with
Tested in the same studies.
Bevacizumab (26) · Sorafenib (19) · Tacrolimus (19) · Paclitaxel (16) · Erlotinib (16) · Carboplatin (16) · Letrozole (14) · Mycophenolic Acid (14)
Studies
Open first, then newest update. How each study uses Everolimus is read from its arms, and is right about nine times in ten.
Testing it · 667
- Efficiency of Everolimus for the Treatment of Kidney Transplanted Patients Presenting a Missing Self-induced NK-mediated RejectionRecruitingNot applicableHospices Civils de LyonNCT03955172Written as Everolimus
- A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.RecruitingPhase 3PfizerNCT07062965Written as Everolimus
- Study of CDK8 Inhibitor RVU120 in Combination With Everolimus in Children With Recurrent or Progressive Group 3 or 4 MedulloblastomaNot yet recruitingPhase 1Bożenna Dembowska BagińskaNCT07865130Written as Everolimus (Afinitor) tablets
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerRecruitingPhase 1/2Hoffmann-La RocheNCT04802759Written as Everolimus
- Everolimus bAsed caLcineurin inhibiTor frEe immunosuppRession oNe Year AfTer lIver transplantatiON (ALTERNATION)RecruitingPhase 3Hannover Medical SchoolNCT07739914Written as Everolimus
- Expanding Liver Transplant Immunosuppression Minimization Via EverolimusRecruitingPhase 2National Institute of Allergy and Infectious Diseases (NIAID)NCT06280950Written as Everolimus
- Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.RecruitingPhase 3MedSIRNCT06382948Written as Everolimus
- Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)RecruitingPhase 1University of California, San FranciscoNCT04485559Written as Everolimus
- Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent SarcomaRecruitingNot applicableM.D. Anderson Cancer CenterNCT04199026Written as Everolimus
- Adapting Treatment to the Tumor Molecular Alterations for Patients With Advanced Solid Tumors: MyOwnSpecificTreatmentRecruitingPhase 2Centre Leon BerardNCT02029001Written as Everolimus (10 mg QD)
- European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory TumorsRecruitingPhase 1/2Gustave Roussy, Cancer Campus, Grand ParisNCT02813135Written as Everolimus
- Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial CancerRecruitingPhase 1M.D. Anderson Cancer CenterNCT07318324Written as Everolimus
- Combination of Everolimus and 177Lu-DOTATATE in the Treatment of Grades 2 and 3 Refractory Meningioma: a Phase IIb Clinical TrialRecruitingPhase 2Central Hospital, Nancy, FranceNCT06126588Written as Everolimus
- Elacestrant With Everolimus for the Treatment of Recurrent Advanced or Metastatic ER-Positive Endometrial CancerNot yet recruitingPhase 2Jonsson Comprehensive Cancer CenterNCT07634601Written as Everolimus
- Double-Blind Trial of Everolimus for Improving Social Abilities in PTEN Germline MutationsNot yet recruitingPhase 2/3Boston Children's HospitalNCT07218575Written as Everolimus blinded oral capsules
- RESTOR: PK/PD mTORi Inhibition in Older AdultsRecruitingEarly Phase 1The University of Texas Health Science Center at San AntonioNCT06658093Written as Everolimus
- Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutantRecruitingPhase 2Nationwide Children's HospitalNCT05843253Written as Everolimus
- Rapalog Pharmacology (RAP PAC) StudyRecruitingPhase 1University of Wisconsin, MadisonNCT05949658Written as Everolimus
- HORUS-Cytomegalovirus Open Proof-of-concept Exploratory TrialNot yet recruitingPhase 4Oriol ManuelNCT07570433Written as Switch from MPA to a mammalian target of rapamycin inhibitor (mTORi), together with an adapted dose of tacrolimus
- FUSCC Refractory TNBC Platform Study (FUTURE2.0)RecruitingPhase 2Fudan UniversityNCT05749588Written as E2: SHR-A1811 with everolimus
See all 667 studies that test Everolimus →
Given in every arm · 46 — Everolimus is usual care beside what is tested
- Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic MalignancyRecruitingPhase 4Dana-Farber Cancer InstituteNCT07426484Written as Everolimus
- Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast CancerRecruitingPhase 1/2Ellipses PharmaNCT05573126Written as Everolimus
- A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BCRecruitingPhase 1/2Forward Pharmaceuticals Co., Ltd.NCT07002177Written as Everolimus 10 mg
- Safety and Efficacy of SYHA1813 Single Agent or in Combination With Different Regimens in Unresectable Locally Advanced or Metastatic Solid Tumors.Not yet recruitingPhase 1/2Shanghai Runshi Pharmaceutical Technology Co., LtdNCT06682611Written as Everolimus
- A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)Active, not recruitingPhase 3Jiangsu Simcere Pharmaceutical Co., Ltd.NCT06680921Written as Everolimus (Afinitor®)
- A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial CancerActive, not recruitingPhase 1Eli Lilly and CompanyNCT04188548Written as Everolimus
- A Study Evaluating the Efficacy and Safety of Giredestrant Plus Everolimus Compared With the Physician's Choice of Endocrine Therapy Plus Everolimus in Participants With Estrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast Cancer (evERA Breast Cancer)Active, not recruitingPhase 3Genentech, Inc.NCT05306340Written as Everolimus
- Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast CancerActive, not recruitingPhase 1/2Stemline Therapeutics, Inc.NCT05563220Written as Everolimus
- A Phase II, Two-Arm Study of Everolimus and Letrozole, +/- Ribociclib (Lee011) in Patients With Advanced or Recurrent Endometrial CarcinomaActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT03008408Written as Everolimus
- A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has SpreadActive, not recruitingPhase 1Eli Lilly and CompanyNCT02057133Written as Everolimus
- Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast CancerTerminatedPhase 1/2SanofiNCT03284957Written as Everolimus
- Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)Active, not recruitingPhase 1AmgenNCT04185883Written as Everolimus
- BI 836845 in Estrogen Receptor Positive Metastatic Breast CancerCompletedPhase 1Boehringer IngelheimNCT02123823Written as Everolimus
- Cemiplimab in AlloSCT/SOT Recipients With CSCCCompletedPhase 1/2Dana-Farber Cancer InstituteNCT04339062Written as Everolimus
- The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has SpreadCompletedPhase 2Boehringer IngelheimNCT03659136Written as Everolimus
- Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With CancerTerminatedPhase 3Alliance for Clinical Trials in OncologyNCT03839940Written as Everolimus
- Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast CancerActive, not recruitingPhase 1Jiangsu Simcere Pharmaceutical Co., Ltd.NCT05293964Written as everolimus
- Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast CancerCompletedPhase 2BayerNCT02258451Written as Everolimus
- First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial CarcinomaTerminatedPhase 2Matthew GalskyNCT01215136Written as Everolimus
- Study to Evaluate Ibrutinib Combination Therapy in Patients With Selected Gastrointestinal and Genitourinary TumorsCompletedPhase 1/2Pharmacyclics LLC.NCT02599324Written as everolimus
Showing 20 of 46.
As the comparator · 29 — what is tested is compared with Everolimus
- Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine TumorsRecruitingPhase 2/3ExelixisNCT06943755Written as Everolimus
- Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0RecruitingPhase 3Gustave Roussy, Cancer Campus, Grand ParisNCT05476939Written as Everolimus
- Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine TumorsRecruitingPhase 2National Cancer Institute (NCI)NCT04665739Written as Everolimus
- Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT TrialRecruitingPhase 2National Cancer Institute (NCI)NCT05773274Written as Everolimus
- A Phase 3 Study of HRS-8080 Versus Treatment Chosen by Physicians in Locally Advanced and Metastatic Breast CancerRecruitingPhase 3Shandong Suncadia Medicine Co., Ltd.NCT07024173Written as Everolimus Tablets
- MTOR Inhibitors in Older AdultsRecruitingPhase 1/2University of Texas Southwestern Medical CenterNCT06727305Written as Everolimus 0.5 MG Oral Tablet
- EVERolimus and LenvAtinib Versus Everolimus for Bone SarcomaNot yet recruitingPhase 2Yonsei UniversityNCT07619950Written as Everolimus
- Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.RecruitingPhase 3Grupo Espanol de Tumores NeuroendocrinosNCT05918302Written as Everolimus
- Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine TumorsRecruitingPhase 2/3CSPC ZhongQi Pharmaceutical Technology Co., Ltd.NCT07165886Written as Everolimus
- A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)Active, not recruitingPhase 3Merck Sharp & Dohme LLCNCT04195750Written as Everolimus
- Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET PatientsActive, not recruitingPhase 3ITM Solucin GmbHNCT03049189Written as Everolimus
- Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)CompletedPhase 2/3HutchmedNCT05522231Written as axitinib / everolimus
- Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA TherapyActive, not recruitingPhase 3RayzeBio, Inc.NCT05477576Written as Everolimus
- Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)Active, not recruitingPhase 2Merck Sharp & Dohme LLCNCT06428396Written as Everolimus
- A Study to Learn About the Study Medicine Called PF-07220060 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of TreatmentActive, not recruitingPhase 2PfizerNCT06105632Written as Everolimus
- Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSEActive, not recruitingPhase 3ITM Solucin GmbHNCT04919226Written as Everolimus
- A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast CancerCompletedPhase 2Queen Mary University of LondonNCT02216786Written as Everolimus
- De Novo Everolimus Versus Tacrolimus in Combination With Mofetil Mycophenolate and Low Dose Corticosteroids to Reduce Tacrolimus Induced Nephrotoxicity in Liver Transplantation: a Prospective, Multicentric, Randomised StudyWithdrawnPhase 3Rennes University HospitalNCT02909335Written as Everolimus
- Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)CompletedPhase 3Bristol-Myers SquibbNCT01668784Written as Everolimus
- MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell CarcinomaCompletedPhase 2Millennium Pharmaceuticals, Inc.NCT02724020Written as Everolimus
Showing 20 of 29.
Codes
What other systems call Everolimus · ClinicalTrials.gg INT006510
- MeSH (NLM) D000068338EverolimusConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 9HW64Q8G6GEVEROLIMUSConfirmed FDA, NLM, Wikidata
- RxNorm 141704Confirmed FDA, Wikidata
- Wikidata Q421052everolimusConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C48387EverolimusOne source FDA
- DrugBank DB01590One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000068338 | Everolimus | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 9HW64Q8G6G | EVEROLIMUS | Confirmed FDA, NLM, Wikidata |
| RxNorm | 141704 | — | Confirmed FDA, Wikidata |
| Wikidata | Q421052 | everolimus | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C48387 | Everolimus | One source FDA |
| DrugBank | DB01590 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.